Literature DB >> 28420656

Posttranslational modification impact on the mechanism by which amyloid-β induces synaptic dysfunction.

Katarzyna M Grochowska1, PingAn Yuanxiang1, Julia Bär1,2, Rajeev Raman1, Gemma Brugal3,4, Giriraj Sahu1, Michaela Schweizer5, Arthur Bikbaev6, Stephan Schilling7, Hans-Ulrich Demuth7, Michael R Kreutz8,9,10.   

Abstract

Oligomeric amyloid-β (Aβ) 1-42 disrupts synaptic function at an early stage of Alzheimer's disease (AD). Multiple posttranslational modifications of Aβ have been identified, among which N-terminally truncated forms are the most abundant. It is not clear, however, whether modified species can induce synaptic dysfunction on their own and how altered biochemical properties can contribute to the synaptotoxic mechanisms. Here, we show that a prominent isoform, pyroglutamated Aβ3(pE)-42, induces synaptic dysfunction to a similar extent like Aβ1-42 but by clearly different mechanisms. In contrast to Aβ1-42, Aβ3(pE)-42 does not directly associate with synaptic membranes or the prion protein but is instead taken up by astrocytes and potently induces glial release of the proinflammatory cytokine TNFα. Moreover, Aβ3(pE)-42-induced synaptic dysfunction is not related to NMDAR signalling and Aβ3(pE)-42-induced impairment of synaptic plasticity cannot be rescued by D1-agonists. Collectively, the data point to a scenario where neuroinflammatory processes together with direct synaptotoxic effects are caused by posttranslational modification of soluble oligomeric Aβ and contribute synergistically to the onset of synaptic dysfunction in AD.
© 2017 The Authors.

Entities:  

Keywords:  Jacob; N‐methyl‐d‐aspartate‐receptor; TNFα; amyloid‐β1‐42; amyloid‐β3(pE)‐42

Mesh:

Substances:

Year:  2017        PMID: 28420656      PMCID: PMC5452034          DOI: 10.15252/embr.201643519

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  63 in total

1.  Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor.

Authors:  Qinwen Wang; Jinqun Wu; Michael J Rowan; Roger Anwyl
Journal:  Eur J Neurosci       Date:  2005-12       Impact factor: 3.386

2.  Early neuronal dysfunction by amyloid β oligomers depends on activation of NR2B-containing NMDA receptors.

Authors:  Raik Rönicke; Marina Mikhaylova; Sabine Rönicke; Jessica Meinhardt; Ulrich H Schröder; Marcus Fändrich; Georg Reiser; Michael R Kreutz; Klaus G Reymann
Journal:  Neurobiol Aging       Date:  2010-02-04       Impact factor: 4.673

3.  Metabotropic NMDA receptor function is required for β-amyloid-induced synaptic depression.

Authors:  Helmut W Kessels; Sadegh Nabavi; Roberto Malinow
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

4.  Fiji: an open-source platform for biological-image analysis.

Authors:  Johannes Schindelin; Ignacio Arganda-Carreras; Erwin Frise; Verena Kaynig; Mark Longair; Tobias Pietzsch; Stephan Preibisch; Curtis Rueden; Stephan Saalfeld; Benjamin Schmid; Jean-Yves Tinevez; Daniel James White; Volker Hartenstein; Kevin Eliceiri; Pavel Tomancak; Albert Cardona
Journal:  Nat Methods       Date:  2012-06-28       Impact factor: 28.547

5.  beta-Amyloid disrupts activity-dependent gene transcription required for memory through the CREB coactivator CRTC1.

Authors:  Judit España; Jorge Valero; Alfredo J Miñano-Molina; Roser Masgrau; Elsa Martín; Cristina Guardia-Laguarta; Alberto Lleó; Lydia Giménez-Llort; José Rodríguez-Alvarez; Carlos A Saura
Journal:  J Neurosci       Date:  2010-07-14       Impact factor: 6.167

Review 6.  Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease.

Authors:  Ji Won Um; Stephen M Strittmatter
Journal:  Prion       Date:  2012-09-17       Impact factor: 3.931

7.  Microglial derived tumor necrosis factor-α drives Alzheimer's disease-related neuronal cell cycle events.

Authors:  Kiran Bhaskar; Nicole Maphis; Guixiang Xu; Nicholas H Varvel; Olga N Kokiko-Cochran; Jason P Weick; Susan M Staugaitis; Astrid Cardona; Richard M Ransohoff; Karl Herrup; Bruce T Lamb
Journal:  Neurobiol Dis       Date:  2013-10-17       Impact factor: 5.996

8.  The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease.

Authors:  Megan Larson; Mathew A Sherman; Fatou Amar; Mario Nuvolone; Julie A Schneider; David A Bennett; Adriano Aguzzi; Sylvain E Lesné
Journal:  J Neurosci       Date:  2012-11-21       Impact factor: 6.167

9.  Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy.

Authors:  Roxanna Perez-Garmendia; Goar Gevorkian
Journal:  Curr Neuropharmacol       Date:  2013-09       Impact factor: 7.363

Review 10.  TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease.

Authors:  Melissa K McCoy; Malú G Tansey
Journal:  J Neuroinflammation       Date:  2008-10-17       Impact factor: 8.322

View more
  16 in total

1.  Posttranslational modification impact on the mechanism by which amyloid-β induces synaptic dysfunction.

Authors:  Katarzyna M Grochowska; PingAn Yuanxiang; Julia Bär; Rajeev Raman; Gemma Brugal; Giriraj Sahu; Michaela Schweizer; Arthur Bikbaev; Stephan Schilling; Hans-Ulrich Demuth; Michael R Kreutz
Journal:  EMBO Rep       Date:  2017-04-18       Impact factor: 8.807

2.  Discovery of a novel pseudo β-hairpin structure of N-truncated amyloid-β for use as a vaccine against Alzheimer's disease.

Authors:  Preeti Bakrania; Gareth Hall; Yvonne Bouter; Caroline Bouter; Nicola Beindorff; Richard Cowan; Sarah Davies; Jemma Price; Chido Mpamhanga; Elizabeth Love; David Matthews; Mark D Carr; Thomas A Bayer
Journal:  Mol Psychiatry       Date:  2021-11-15       Impact factor: 15.992

Review 3.  Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?

Authors:  Julie Dunys; Audrey Valverde; Frédéric Checler
Journal:  J Biol Chem       Date:  2018-08-24       Impact factor: 5.157

4.  Abelson Kinases Mediate the Depression of Spontaneous Synaptic Activity Induced by Amyloid Beta 1-42 Peptides.

Authors:  M Reichenstein; N Borovok; A Sheinin; T Brider; I Michaelevski
Journal:  Cell Mol Neurobiol       Date:  2020-05-12       Impact factor: 5.046

5.  Amyloid β42 peptide is toxic to non-neural cells in Drosophila yielding a characteristic metabolite profile and the effect can be suppressed by PI3K.

Authors:  Mercedes Arnés; Sergio Casas-Tintó; Anders Malmendal; Alberto Ferrús
Journal:  Biol Open       Date:  2017-11-15       Impact factor: 2.422

6.  Endophilin2 Interacts with GluA1 to Mediate AMPA Receptor Endocytosis Induced by Oligomeric Amyloid-β.

Authors:  Jifeng Zhang; Yichen Yin; Zhisheng Ji; Zhenbin Cai; Bo Zhao; Jiong Li; Minghui Tan; Guoqing Guo
Journal:  Neural Plast       Date:  2017-07-05       Impact factor: 3.599

7.  N-Methyl-D-Aspartate Receptor Link to the MAP Kinase Pathway in Cortical and Hippocampal Neurons and Microglia Is Dependent on Calcium Sensors and Is Blocked by α-Synuclein, Tau, and Phospho-Tau in Non-transgenic and Transgenic APPSw,Ind Mice.

Authors:  Rafael Franco; David Aguinaga; Irene Reyes; Enric I Canela; Jaume Lillo; Airi Tarutani; Masato Hasegawa; Anna Del Ser-Badia; José A Del Rio; Michael R Kreutz; Carlos A Saura; Gemma Navarro
Journal:  Front Mol Neurosci       Date:  2018-08-28       Impact factor: 5.639

8.  Virulent Pseudomonas aeruginosa infection converts antimicrobial amyloids into cytotoxic prions.

Authors:  Sarah Voth; Meredith Gwin; Christopher Michael Francis; Ron Balczon; Dara W Frank; Jean-Francois Pittet; Brant M Wagener; Stephen A Moser; Mikhail Alexeyev; Nicole Housley; Jonathon P Audia; Scott Piechocki; Kayla Madera; Autumn Simmons; Michaela Crawford; Troy Stevens
Journal:  FASEB J       Date:  2020-05-15       Impact factor: 5.191

9.  Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.

Authors:  Philip Scheltens; Merja Hallikainen; Timo Grimmer; Thomas Duning; Alida A Gouw; Charlotte E Teunissen; Alle Meije Wink; Paul Maruff; John Harrison; Caroline M van Baal; Suzanne Bruins; Inge Lues; Niels D Prins
Journal:  Alzheimers Res Ther       Date:  2018-10-12       Impact factor: 6.982

10.  Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activation.

Authors:  Thore Hettmann; Stephen D Gillies; Martin Kleinschmidt; Anke Piechotta; Koki Makioka; Cynthia A Lemere; Stephan Schilling; Jens-Ulrich Rahfeld; Inge Lues
Journal:  Sci Rep       Date:  2020-02-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.